Standard BioTools to Announce Q4 Earnings on February 24
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Source: seekingalpha
- Earnings Announcement Date: Standard BioTools is set to release its Q4 earnings on February 24 after market close, with a consensus EPS estimate of -$0.03, reflecting a 66.7% year-over-year increase, while revenue is expected to decline by 60.4% to $18.5 million, indicating significant challenges ahead.
- Historical Performance Review: Over the past year, Standard BioTools has only beaten EPS estimates 25% of the time, while achieving a 100% success rate in beating revenue estimates, suggesting stability in revenue management but a need for improvement in profitability.
- 2025 Outlook: The company reported preliminary revenue of $85 million from continuing operations for 2025, exceeding estimates, although the overall outlook remains murky, which could impact investor confidence.
- Market Reaction Expectations: Given the significant revenue decline indicated in the upcoming earnings report, market reactions to Standard BioTools may lean negative, prompting investors to closely monitor how the company addresses its current financial challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LAB
Wall Street analysts forecast LAB stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 0.810
Low
1.35
Averages
1.35
High
1.35
Current: 0.810
Low
1.35
Averages
1.35
High
1.35
About LAB
Standard BioTools Inc. has a portfolio of technologies that help biomedical researchers develop medicines faster. The Company develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The Company's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Investigation: Potential Violations in Multiple Company Transactions
- Transaction Investigation: Halper Sadeh LLC is investigating Open Lending Corporation (NASDAQ: LPRO)'s sale to ANV Group Holdings Ltd. for $3.15 per share, which may involve breaches of fiduciary duties impacting shareholder rights.
- Merger Scrutiny: The sale of Huntsman Corporation (NYSE: HUN) to Olin Corporation for 0.5476 shares of Olin per Huntsman share is under review, potentially limiting superior competing offers and affecting shareholder options.
- Cash Acquisition: AstroNova, Inc. (NASDAQ: ALOT) is being sold to Arcline Investment Management for $29.00 per share in cash, with Halper Sadeh LLC possibly seeking increased compensation and disclosures for shareholders.
- Ownership Stake Post-Merger: Standard BioTools Inc. (NASDAQ: LAB)'s merger with Treeline Biosciences, Inc. is expected to result in Standard BioTools shareholders owning approximately 16% of the combined entity, prompting Halper Sadeh LLC to advocate for enhanced shareholder rights.
See More
Investigation Alerts for Multiple Company Mergers
- AstroNova Acquisition Investigation: AstroNova is set to be acquired by Arcline Investment Management for $29.00 per share in an all-cash deal valued at approximately $272 million, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Open Lending Merger Scrutiny: Open Lending will be acquired by ANV Group Holdings Ltd. for $3.15 per share, with investigations examining whether the board failed to secure fair value for shareholders, potentially impacting their interests.
- Huntsman Merger Inquiry: Huntsman will be acquired in a deal where shareholders receive 0.5476 shares of Olin for each Huntsman share, with Olin shareholders owning about 54.5% post-merger, and investigations looking into whether the board conducted a fair process affecting shareholder rights.
- Standard BioTools Merger Review: Standard BioTools is to be acquired by Treeline Biosciences, with pre-merger shareholders expected to own about 16% of the combined entity, and investigations assessing whether the board fulfilled fiduciary duties to ensure fair transaction terms for shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating companies like Roku, Inc., Payoneer Global Inc., and Standard BioTools Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Roku Transaction Details: Roku is set to be sold to Fox Corporation for $96.00 in cash and 0.9693 shares of Fox Class A common stock per Roku share, with Fox shareholders expected to own approximately 73% of the combined entity, potentially affecting its market position.
- Payoneer Acquisition Status: Payoneer Global Inc. is being sold to Nuvei for $7.40 per share in cash, and Halper Sadeh LLC may seek increased compensation for shareholders to ensure their rights are protected during the transaction.
- Standard BioTools Merger: The merger between Standard BioTools Inc. and Treeline Biosciences, Inc. is expected to result in Standard BioTools shareholders owning about 16% of the combined company, with Halper Sadeh LLC representing shareholders in seeking additional disclosures and compensation.
See More
Pacific Ridge Exploration Partners with Labrador Gold for 2026 Exploration
- Exploration Program Launch: Labrador Gold Corp. has announced plans for a 2026 exploration program at Pacific Ridge's Mariposa and Eureka Dome gold projects, with total expenditures expected to reach $5.4 million, reflecting strong confidence in the area's gold potential.
- Acquisition Terms Defined: Labrador Gold plans to fully acquire Mariposa and Eureka Dome by making cash payments of $500,000 and issuing 6,670,000 shares over four years, further solidifying its market position in the White Gold District.
- Multi-Phase Exploration: The Mariposa project will undergo an 808-kilometer high-resolution aeromagnetic survey and a detailed LiDAR survey with approximately 4,700 soil samples, aimed at enhancing exploration efficiency and accelerating resource assessment processes.
- Active Regional Market: With companies like Talamore Mining actively developing in the White Gold District, Pacific Ridge's projects are poised to benefit from the increasing gold exploration activities in the region, enhancing its competitive edge in the market.
See More
Standard BioTools and Treeline to Merge in All-Stock Deal
- Merger Overview: Standard BioTools has announced an all-stock merger agreement with Treeline Biosciences, valuing the transaction at approximately $460 million, including $10 million in cash, expected to close in the second half of 2026.
- Shareholder Structure Change: Post-merger, pre-merger Standard BioTools shareholders will own about 16% of the combined entity, while Treeline shareholders will hold the remainder, indicating a significant shift in shareholder interests.
- Enhanced Financial Position: The combined company is projected to have over $900 million in cash, sufficient to fund operations into 2029, while adding approximately $450 million in net cash to its balance sheet, thereby strengthening financial stability.
- Strategic Business Adjustments: Treeline does not plan to operate Standard BioTools's Mass Cytometry and Microfluidics businesses, with Standard BioTools exploring various options to maximize the value of these units, reflecting a focus on resource optimization.
See More
Standard BioTools Merges with Treeline Biosciences to Enhance Drug Development Pipeline
- Merger Overview: Standard BioTools has entered into a merger agreement with Treeline, expected to close in the second half of 2026, with the combined entity operating as Treeline Biosciences and trading on Nasdaq under the ticker TRLN.
- Enhanced Financial Strength: The merger is projected to provide the combined company with over $900 million in cash, including approximately $450 million in net cash from Standard BioTools, ensuring operational funding through 2029 and supporting long-term growth.
- Clinical Program Advancements: Treeline currently has three Phase 1 clinical trials underway, with multiple anticipated data readouts starting in 2027, focusing on oncology, neurology, and immunology, highlighting its potential in the biopharma sector.
- Management Team Strength: Following the merger, Treeline's co-founder Josh Bilenker will serve as CEO, leveraging his extensive drug development experience to drive the company's growth in precision medicine.
See More
Investor Rights Investigation: Potential Violations in Multiple Company Transactions
- Transaction Investigation: Halper Sadeh LLC is investigating Open Lending Corporation (NASDAQ: LPRO)'s sale to ANV Group Holdings Ltd. for $3.15 per share, which may involve breaches of fiduciary duties impacting shareholder rights.
- Merger Scrutiny: The sale of Huntsman Corporation (NYSE: HUN) to Olin Corporation for 0.5476 shares of Olin per Huntsman share is under review, potentially limiting superior competing offers and affecting shareholder options.
- Cash Acquisition: AstroNova, Inc. (NASDAQ: ALOT) is being sold to Arcline Investment Management for $29.00 per share in cash, with Halper Sadeh LLC possibly seeking increased compensation and disclosures for shareholders.
- Ownership Stake Post-Merger: Standard BioTools Inc. (NASDAQ: LAB)'s merger with Treeline Biosciences, Inc. is expected to result in Standard BioTools shareholders owning approximately 16% of the combined entity, prompting Halper Sadeh LLC to advocate for enhanced shareholder rights.
See More
Investigation Alerts for Multiple Company Mergers
- AstroNova Acquisition Investigation: AstroNova is set to be acquired by Arcline Investment Management for $29.00 per share in an all-cash deal valued at approximately $272 million, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Open Lending Merger Scrutiny: Open Lending will be acquired by ANV Group Holdings Ltd. for $3.15 per share, with investigations examining whether the board failed to secure fair value for shareholders, potentially impacting their interests.
- Huntsman Merger Inquiry: Huntsman will be acquired in a deal where shareholders receive 0.5476 shares of Olin for each Huntsman share, with Olin shareholders owning about 54.5% post-merger, and investigations looking into whether the board conducted a fair process affecting shareholder rights.
- Standard BioTools Merger Review: Standard BioTools is to be acquired by Treeline Biosciences, with pre-merger shareholders expected to own about 16% of the combined entity, and investigations assessing whether the board fulfilled fiduciary duties to ensure fair transaction terms for shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating companies like Roku, Inc., Payoneer Global Inc., and Standard BioTools Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Roku Transaction Details: Roku is set to be sold to Fox Corporation for $96.00 in cash and 0.9693 shares of Fox Class A common stock per Roku share, with Fox shareholders expected to own approximately 73% of the combined entity, potentially affecting its market position.
- Payoneer Acquisition Status: Payoneer Global Inc. is being sold to Nuvei for $7.40 per share in cash, and Halper Sadeh LLC may seek increased compensation for shareholders to ensure their rights are protected during the transaction.
- Standard BioTools Merger: The merger between Standard BioTools Inc. and Treeline Biosciences, Inc. is expected to result in Standard BioTools shareholders owning about 16% of the combined company, with Halper Sadeh LLC representing shareholders in seeking additional disclosures and compensation.
See More
Pacific Ridge Exploration Partners with Labrador Gold for 2026 Exploration
- Exploration Program Launch: Labrador Gold Corp. has announced plans for a 2026 exploration program at Pacific Ridge's Mariposa and Eureka Dome gold projects, with total expenditures expected to reach $5.4 million, reflecting strong confidence in the area's gold potential.
- Acquisition Terms Defined: Labrador Gold plans to fully acquire Mariposa and Eureka Dome by making cash payments of $500,000 and issuing 6,670,000 shares over four years, further solidifying its market position in the White Gold District.
- Multi-Phase Exploration: The Mariposa project will undergo an 808-kilometer high-resolution aeromagnetic survey and a detailed LiDAR survey with approximately 4,700 soil samples, aimed at enhancing exploration efficiency and accelerating resource assessment processes.
- Active Regional Market: With companies like Talamore Mining actively developing in the White Gold District, Pacific Ridge's projects are poised to benefit from the increasing gold exploration activities in the region, enhancing its competitive edge in the market.
See More
Standard BioTools and Treeline to Merge in All-Stock Deal
- Merger Overview: Standard BioTools has announced an all-stock merger agreement with Treeline Biosciences, valuing the transaction at approximately $460 million, including $10 million in cash, expected to close in the second half of 2026.
- Shareholder Structure Change: Post-merger, pre-merger Standard BioTools shareholders will own about 16% of the combined entity, while Treeline shareholders will hold the remainder, indicating a significant shift in shareholder interests.
- Enhanced Financial Position: The combined company is projected to have over $900 million in cash, sufficient to fund operations into 2029, while adding approximately $450 million in net cash to its balance sheet, thereby strengthening financial stability.
- Strategic Business Adjustments: Treeline does not plan to operate Standard BioTools's Mass Cytometry and Microfluidics businesses, with Standard BioTools exploring various options to maximize the value of these units, reflecting a focus on resource optimization.
See More
Standard BioTools Merges with Treeline Biosciences to Enhance Drug Development Pipeline
- Merger Overview: Standard BioTools has entered into a merger agreement with Treeline, expected to close in the second half of 2026, with the combined entity operating as Treeline Biosciences and trading on Nasdaq under the ticker TRLN.
- Enhanced Financial Strength: The merger is projected to provide the combined company with over $900 million in cash, including approximately $450 million in net cash from Standard BioTools, ensuring operational funding through 2029 and supporting long-term growth.
- Clinical Program Advancements: Treeline currently has three Phase 1 clinical trials underway, with multiple anticipated data readouts starting in 2027, focusing on oncology, neurology, and immunology, highlighting its potential in the biopharma sector.
- Management Team Strength: Following the merger, Treeline's co-founder Josh Bilenker will serve as CEO, leveraging his extensive drug development experience to drive the company's growth in precision medicine.
See More
